NCT04398680 2025-12-04
DREAMM 13
GlaxoSmithKline
Phase 1 Withdrawn
Clinical Trials
106 trialsNCT02315157 2025-10-15
Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma
Thomas Jefferson University
Phase 1 Withdrawn
NCT01125449 2025-05-18
Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease
Situs Cancer Research Center
Phase 2 Withdrawn
NCT06352866 2025-03-03
Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT06411301 2025-01-31
AcTRESS
Jules Bordet Institute
Phase 1 Withdrawn
NCT02298816 2024-10-03
HMvax-Regist
Wake Forest University Health Sciences
Withdrawn
NCT03000634 2024-09-05
2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
University of Arkansas
Phase 2 Withdrawn
NCT05050305 2024-07-16
Marizomib Central Nervous System (CNS)
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT05820763 2024-07-10
Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
Washington University School of Medicine
Phase 2 Withdrawn
NCT05204160 2024-07-03
Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy
Emory University
Phase 2 Withdrawn
NCT06400264 2024-05-06
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT05950113 2024-05-01
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT05013437 2024-04-02
AHCT
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Withdrawn
NCT04466475 2024-01-31
Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1 Withdrawn
NCT05980507 2023-12-22
An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital of Soochow University
Phase 1 Withdrawn
NCT05647512 2023-11-18
Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
LaNova Medicines Limited
Phase 1/2 Withdrawn
NCT05321862 2023-11-15
PENTI-MIDAS
Nantes University Hospital
Phase 2 Withdrawn
NCT04258683 2023-08-29
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
Canadian Myeloma Research Group
Phase 2 Withdrawn
NCT05918250 2023-08-18
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
ModernaTX, Inc.
Phase 1 Withdrawn
NCT05513612 2023-03-01
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
Shanghai Pudong Hospital
Phase 1 Withdrawn
NCT02389543 2023-01-26
SLAM
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT02628704 2023-01-26
SCORE
Karyopharm Therapeutics Inc
Phase 2 Withdrawn
NCT00995059 2023-01-05
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
Mayo Clinic
Phase 1/2 Withdrawn
NCT04223661 2022-12-08
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
Indiana University
Phase 2 Withdrawn
NCT04998747 2022-09-27
ProxiMMity-1
Amgen
Phase 1 Withdrawn
NCT04802031 2022-07-07
Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma
University of California, San Francisco
Phase 2 Withdrawn
NCT04467281 2022-07-01
A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Withdrawn
NCT03841565 2022-06-15
Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Academic and Community Cancer Research United
Phase 2 Withdrawn
NCT03660072 2022-05-27
Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma
Bristol-Myers Squibb
Withdrawn
NCT03492268 2022-05-17
Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma
Bioray Laboratories
Phase NA Withdrawn
NCT05170789 2022-05-04
ESdRRMM
Tulane University
Phase 2 Withdrawn
NCT05183139 2022-05-03
US MM-7
Takeda
Phase 4 Withdrawn
NCT04361851 2022-04-26
Study of Dara-Pembro for Multiple Myeloma Patients
Wake Forest University Health Sciences
Phase 2 Withdrawn
NCT04230031 2022-04-21
Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma
Wake Forest University Health Sciences
Phase 2 Withdrawn
NCT04150692 2022-01-24
Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma
Washington University School of Medicine
Phase 2 Withdrawn
NCT02589860 2022-01-10
Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
Indiana University
Withdrawn
NCT04918511 2021-11-26
COAST
Oncopeptides AB
Phase 1 Withdrawn
NCT04464889 2021-10-08
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Medigene AG
Phase 1 Withdrawn
NCT04584307 2021-08-23
Immuno-POWER
Big Ten Cancer Research Consortium
Phase 2 Withdrawn
NCT04288765 2021-07-09
Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma
Grupo Cooperativo de HemopatÃas Malignas
Phase 3 Withdrawn
NCT04621955 2020-11-09
KARE-2
Universitaire Ziekenhuizen KU Leuven
Withdrawn
NCT02786485 2020-10-05
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
Bellicum Pharmaceuticals
Phase 1 Withdrawn
NCT04355039 2020-08-19
INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
Medical College of Wisconsin
Phase 1 Withdrawn
NCT03506802 2020-07-24
NYSCT MM
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT04439305 2020-07-20
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT03145870 2020-07-17
Prevalence of Asymptomatic Thrombosis in Multiple Myeloma
Centre Hospitalier Universitaire, Amiens
Phase NA Withdrawn
NCT03983486 2020-07-17
CIF-PM
Centre Hospitalier Universitaire, Amiens
Withdrawn
NCT03003728 2020-07-10
2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
University of Arkansas
Phase 2 Withdrawn
NCT04024384 2020-03-27
DARALLO
Assistance Publique - Hôpitaux de Paris
Phase 2 Withdrawn
NCT03328936 2020-02-21
Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant
Ohio State University Comprehensive Cancer Center
Phase 2 Withdrawn